Main Article Content
Rotenone is a chemical that has been used to induce Parkinsonism-like behavioral symptoms such as tremor, bradykinesia, rigidity and postural instability in rats. In this study, we used rotenone to induce parkinsonism-like symptoms in rats. Eighteen Wistar rats were randomly divided into three groups: control group, 2.5 mg/kg, rotenone-treated group and 2.5 mg/kg rotenone+10 mg/kg Sinemetâ group. Rotenone was dissolved in soybean oil and injected subcutaneously every day excluding weekends. After 9 doses of soybean oil or rotenone, a series of oral doses of 3% (w/v) acacia or 10 mg/kg Sinemetâ was administered daily for 5 days, followed by a dose of acacia+soybean oil, acacia+rotenone, or Sinemetâ+rotenone. Animal behavior was assessed by using force plate actimeter. The results showed a significant decrease in motor ability of rats injected with rotenone compared to control group. Oral treatment of 10 mg/kg Sinemetâ improved the movement of rotenone-treated rats. Power spectra revealed that the parkinsonian features induced by rotenone possessed the frequency between 0.5-2.5 Hz and 4-12 Hz. This is the first model that applies the behavioral assessment using force plate actimeter in rotenone-induced parkinsonism in rats and thus may be used for evaluating new anti-parkinsonian drugs.
Upon acceptance of an article, the Pharmacological and Therapeutic Society of Thailand will have exclusive right to publish and distribute the article in all forms and media and grant rights to others. Authors have rights to use and share their own published articles.
Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368–376.
Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci. 2000;16:135–142.
Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013;62:132–144.
Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet Neurol. 2004;363:1783–1793.
. Krüger R,Kuhn W,Müller T,Woitalla D,Graeber M,Kösel S,Przuntek H,Epplen JT, Schöls L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet. 1998;18:106–108.
. Polymeropoulos MH ,Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease.Science. 1997;276(5321):2045-7.
. Kitada T,Asakawa S,Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y,Shimizu N.Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.Nature. 1998;392(6676):605-8.
Sherer TB, Betarbet R, Greenamyre JT Environment, mitochondria, and Parkinson’s disease.Neuroscientist. 2002;8(3):192-7.
Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology.1998; 50(5):1346-50.
Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson’s disease. Neurology. 1993; 43:1150–8.
Saiful IZ, Mohamad RS and Ramlan AA. Study of Rotenone from Derris Roots of Varies Location, Plant Parts and Types of Solvent Used. Adv in Environ Bio. 2014;8(2):445-449.
Betarbet R, Sherer TB, Gillian McK, Monica G, Alexander VP and Greenamyre.JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat neurosci. 2000;3(12):1301-1306.
Sherer TB, Betabert R, Testa CM, Seo BB, Richardson JR, Kin JH, Miller GW, Yagi T, Greenamyre JT. Mechanism of Toxicity in Rotenone Models of Parkinson's Disease. J Neurosci. 2003;23(34): 10756-10764.
Alam A, Schmidt WJ. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res. 2002;136(1):317-24.
Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol. 2003;179(1):9–16.
Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT. A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis. 2009;34(2):279-90.
Fowler SC, Birkestrand BR, Chen R, Moss SJ, Vorontsova E, Wang G, Zarcone TJ. A force-plate actometer for quantitating rodent behaviors: illustrative data on locomotion, rotation, spatial patterning, stereotypies, and tremor. J Neurosci Methods. 2001;107(1-2):107-24.
Fowler SC. Behavioral Spectoscopy with the Force-Plate Actometer. Curr sep. 2002;20(1):17-22.
Wang G, Fowler SC. Concurrent quantification of tremor and depression of locomotor activity induced in rats by harmaline and physostigmine. Psychopharmacology (Berl). 2001;158(3):273-80.
Zbigniew KB, Sumit S, Lamya MS, Bobby G, Michael AB, Syed FA, Merle GP, Syed ZI. Chronic exposure to rotenone, a dopaminergic toxin, results in peripheral neuropathy associated with dopaminergic damage. Neuroscience Lett. 2013;541:233–7.
Alexander K, Darryl CG, Alexandra MS, Keri LC, Nadine AT, William GT, Gerlinde AM. Dose-dependent loss of motor function after unilateral medial forebrain bundle rotenone lesion in rats: A cautionary note. Behav Brain Res. 2011;222(1):33-42.
Xiong et al. Edaravone Guards Dopamine Neurons in a Rotenone Model for Parkinson's Disease. PLoS One. 2011;6(6):e20677